# Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

> **NCT03890289** · PHASE2 · TERMINATED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 5 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Idelalisib
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT03890289
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-18
- **Primary completion:** 2021-04-29
- **Final completion:** 2023-05-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study was halted prematurely due to safety, since tocity stopping rules have been met
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03890289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03890289, "Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03890289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*